Integer (NYSE:ITGR) Hits New 52-Week Low - Here's What Happened

Key Points

• Integer Holdings Corporation's stock hit a new 52-week low of $103.29 on Wednesday, down from a previous close of $105.52.
• Analysts have mixed ratings on the stock, with upgrades from Citigroup to a "strong-buy" and potential price targets ranging from $132.00 to $145.00.
• Integer reported quarterly earnings with an EPS of $1.55, slightly missing estimates, but showed an 11.4% revenue increase year-over-year.

Integer Holdings Corporation (NYSE:ITGR - Get Free Report)'s share price reached a new 52-week low during trading on Wednesday . The stock traded as low as $103.60 and last traded at $103.29, with a volume of 24091 shares changing hands. The stock had previously closed at $105.52.

Wall Street Analyst Weigh In

Several research firms recently commented on ITGR. Citigroup upgraded Integer from a "hold" rating to a "strong-buy" rating and upped their price objective for the company from $133.00 to $140.00 in a research note on Thursday, May 22nd. Wells Fargo & Company dropped their target price on Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a research report on Friday, July 25th. Truist Financial dropped their target price on Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a research report on Friday, July 25th. Wall Street Zen upgraded Integer from a "hold" rating to a "buy" rating in a research report on Saturday, August 30th. Finally, Raymond James Financial dropped their target price on Integer from $150.00 to $143.00 and set an "outperform" rating on the stock in a research report on Friday, July 25th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $140.25.

Integer Trading Down 1.2%

The stock has a market cap of $3.51 billion, a P/E ratio of 44.10, a PEG ratio of 0.80 and a beta of 1.03. The firm's fifty day moving average price is $109.53 and its two-hundred day moving average price is $115.83. The company has a debt-to-equity ratio of 0.72, a current ratio of 3.41 and a quick ratio of 2.18.

Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.02). The firm had revenue of $476.00 million during the quarter, compared to the consensus estimate of $464.37 million. Integer had a return on equity of 12.27% and a net margin of 4.61%.The company's revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.30 EPS. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. As a group, equities research analysts forecast that Integer Holdings Corporation will post 6.01 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. AdvisorNet Financial Inc bought a new position in Integer in the first quarter valued at $28,000. Opal Wealth Advisors LLC bought a new position in Integer in the first quarter valued at $28,000. Bessemer Group Inc. increased its stake in Integer by 73.1% in the first quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 125 shares during the last quarter. SVB Wealth LLC bought a new position in Integer in the first quarter valued at $35,000. Finally, CWM LLC increased its stake in Integer by 46.1% in the second quarter. CWM LLC now owns 355 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 112 shares during the last quarter. Institutional investors own 99.29% of the company's stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.